Abstract
Stroke is one of the leading causes of morbidity and mortality in the world. The majority of strokes is ischemic. Unfortunately, there is still not well substantial treatment option to increase the survival and alleviate the outcome after ischemic stroke. In the central nervous system, progranulin (PGRN) is considered to play important roles in the maintenance of physiological functions. Mutations in the gene that encodes PGRN cause transactive response DNA-binding protein 43-positive frontotemporal lobar degeneration. Several studies have reported that PGRN exerts protective effects against ischemic brain injury. PGRN alleviates the impairments after acute focal cerebral ischemia by a variety of mechanisms, which we call “brain protection”. This includes neuroprotection, suppression of neuroinflammation, and attenuation of blood-brain barrier disruption, i.e., vascular protection. PGRN has pleiotropic protective effects and is, therefore, an ideal candidate molecule for the therapy of stroke. We will accelerate the research towards further development of PGRN-based treatments of stroke.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
